Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

A ‘click’ chemistry approach to novel entinostat (MS-275) based class I histone deacetylase proteolysis targeting chimeras
Jasmine M. Cross, Megan E. Coulson, Joshua P. Smalley, et al.
RSC Medicinal Chemistry (2022) Vol. 13, Iss. 12, pp. 1634-1639
Open Access | Times Cited: 16

Showing 16 citing articles:

HDAC-targeting epigenetic modulators for cancer immunotherapy
Binbin Cheng, Wei Pan, Yao Xiao, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116129-116129
Closed Access | Times Cited: 35
Characteristic roadmap of linker governs the rational design of PROTACs
Yawen Dong, Tingting Ma, Ting Xu, et al.
Acta Pharmaceutica Sinica B (2024) Vol. 14, Iss. 10, pp. 4266-4295
Open Access | Times Cited: 26
A beginner’s guide to current synthetic linker strategies towards VHL-recruiting PROTACs
Nikol A. Zografou-Barredo, Alex J. Hallatt, J. S. JUN. RICCI, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 88-89, pp. 117334-117334
Open Access | Times Cited: 35
Overview of epigenetic degraders based on PROTAC, molecular glue, and hydrophobic tagging technologies
Xiaopeng Peng, Zhihao Hu, Limei Zeng, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 2, pp. 533-578
Open Access | Times Cited: 27
PROTACs: A novel strategy for cancer drug discovery and development
Xin Han, Yi Sun
MedComm (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 25
Collateral lethality between HDAC1 and HDAC2 exploits cancer-specific NuRD complex vulnerabilities
Yuxiang Zhang, David Remillard, Ugoma Onubogu, et al.
Nature Structural & Molecular Biology (2023) Vol. 30, Iss. 8, pp. 1160-1171
Open Access | Times Cited: 17
Perspectives and new aspects of histone deacetylase inhibitors in the therapy of CNS diseases
Bo Han, Mengfei Wang, Jiayi Li, et al.
European Journal of Medicinal Chemistry (2023) Vol. 258, pp. 115613-115613
Closed Access | Times Cited: 16
Overview of Class I HDAC Modulators: Inhibitors and Degraders
Ziqian Huang, Limei Zeng, Binbin Cheng, et al.
European Journal of Medicinal Chemistry (2024) Vol. 276, pp. 116696-116696
Closed Access | Times Cited: 5
Discovery of a potential hematologic malignancies therapy: Selective and potent HDAC7 PROTAC degrader targeting non-enzymatic function
Yuheng Jin, Xuxin Qi, Xiaoli Yu, et al.
Acta Pharmaceutica Sinica B (2025)
Open Access
PROTAC chemical probes for histone deacetylase enzymes
Urvashi Patel, Joshua P. Smalley, James T. Hodgkinson
RSC Chemical Biology (2023) Vol. 4, Iss. 9, pp. 623-634
Open Access | Times Cited: 9
Exploring the landscape of post-translational modification in drug discovery
Yuhao Cao, Tianyi Yu, Zhiguang Zhu, et al.
Pharmacology & Therapeutics (2024) Vol. 265, pp. 108749-108749
Closed Access | Times Cited: 3
Bifunctional robots inducing targeted protein degradation
M. Elizabeth Sobhia, Harish Kumar, Sonia Kumari
European Journal of Medicinal Chemistry (2023) Vol. 255, pp. 115384-115384
Closed Access | Times Cited: 7
MDM2 Antagonist Idasanutlin Reduces HDAC1/2 Abundance and Corepressor Partners but Not HDAC3
Joshua P. Smalley, Shaun M. Cowley, James T. Hodgkinson
ACS Medicinal Chemistry Letters (2023) Vol. 15, Iss. 1, pp. 93-98
Open Access | Times Cited: 6
Targeting reversible post-translational modifications with PROTACs: a focus on enzymes modifying protein lysine and arginine residues
Marta Pichlak, Tomasz Sobierajski, K. M. Błażewska, et al.
Journal of Enzyme Inhibition and Medicinal Chemistry (2023) Vol. 38, Iss. 1
Open Access | Times Cited: 4
Examination of the Impact of Triazole Position within Linkers on Solubility and Lipophilicity of a CDK9 Degrader Series
Oluwatosin R. Ayinde, Chia Sharpe, Emily Stahl, et al.
ACS Medicinal Chemistry Letters (2023) Vol. 14, Iss. 7, pp. 936-942
Closed Access | Times Cited: 3
Cereblon-recruiting proteolysis targeting chimeras (PROTACs) can determine the selective degradation of HDAC1 over HDAC3
Aline Renata Pavan, Joshua P. Smalley, Urvashi Patel, et al.
Chemical Communications (2024)
Open Access
Page 1

Scroll to top